The endocannabinoid system: directing eating behavior and macronutrient metabolism

For many years, the brain has been the primary focus for research on eating behavior. More recently, the discovery of the endocannabinoids (EC) and the endocannabinoid system (ECS), as well as the characterization of its actions on appetite and metabolism, has provided greater insight on the brain and food intake. The purpose of this review is to explain the actions of EC in the brain and other organs as well as their precursor polyunsaturated fatty acids (PUFA) that are converted to these endogenous ligands. The binding of the EC to the cannabinoid receptors in the brain stimulates food intake, and the ECS participates in systemic macronutrient metabolism where the gastrointestinal system, liver, muscle, and adipose are involved. The EC are biosynthesized from two distinct families of dietary PUFA, namely the n-6 and n-3. Based on their biochemistry, these PUFA are well known to exert considerable physiological and health-promoting actions. However, little is known about how these different families of PUFA compete as precursor ligands of cannabinoid receptors to stimulate appetite or perhaps down-regulate the ECS to amend food intake and prevent or control obesity. The goal of this review is to assess the current available research on ECS and food intake, suggest research that may improve the complications associated with obesity and diabetes by dietary PUFA intervention, and further reveal mechanisms to elucidate the relationships between substrate for EC synthesis, ligand actions on receptors, and the physiological consequences of the ECS. Dietary PUFA are lifestyle factors that could potentially curb eating behavior, which may translate to changes in macronutrient metabolism, systemically and in muscle, benefiting health overall.

[1]  B. Watkins,et al.  Cannabinoid receptor antagonists and fatty acids alter endocannabinoid system gene expression and COX activity. , 2014, The Journal of nutritional biochemistry.

[2]  G. Kaebnick Care and feeding. , 2014, The Hastings Center report.

[3]  B. Watkins,et al.  Dietary DHA supports glucose use by muscle in association with improved endocannabinoid system gene expression in C57/blk6 mice (248.7) , 2014 .

[4]  B. Watkins,et al.  Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts , 2014, Front. Physiol..

[5]  V. Di Marzo,et al.  Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System , 2014, PloS one.

[6]  Beat Lutz,et al.  The endocannabinoid system controls food intake via olfactory processes , 2014, Nature Neuroscience.

[7]  B. Watkins,et al.  Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity. , 2013, Prostaglandins & other lipid mediators.

[8]  A. McAinch,et al.  Fatty Acid Modulation of the Endocannabinoid System and the Effect on Food Intake and Metabolism , 2013, International journal of endocrinology.

[9]  R. Mechoulam,et al.  The endocannabinoid system and the brain. , 2013, Annual review of psychology.

[10]  A. Bilkei-Gorzo,et al.  The endocannabinoid system in normal and pathological brain ageing , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[11]  J. Deschamps,et al.  Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. , 2012, Cell metabolism.

[12]  B. Watkins,et al.  Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. , 2012, The Journal of nutritional biochemistry.

[13]  K. Verhoeckx,et al.  Metabolic Effects of n-3 PUFA as Phospholipids Are Superior to Triglycerides in Mice Fed a High-Fat Diet: Possible Role of Endocannabinoids , 2012, PloS one.

[14]  K. Kristiansen,et al.  Dietary Linoleic Acid Elevates Endogenous 2-AG and Anandamide and Induces Obesity , 2012, Obesity.

[15]  S. Heymsfield,et al.  Challenges and opportunities of defining clinical leptin resistance. , 2012, Cell metabolism.

[16]  D. Cota,et al.  The role of the endocannabinoid system in the neuroendocrine regulation of energy balance , 2012, Journal of psychopharmacology.

[17]  B. Watkins,et al.  Endocannabinoid signaling and energy metabolism: a target for dietary intervention. , 2011, Nutrition.

[18]  O. Manzoni,et al.  Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions , 2011, Nature Neuroscience.

[19]  Lindsay K. Eller,et al.  The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat , 2011, Pharmacology Biochemistry and Behavior.

[20]  M. F. Seifert,et al.  The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health. , 2010, The Journal of nutritional biochemistry.

[21]  Rudolph L. Leibel,et al.  Obesity and leptin resistance: distinguishing cause from effect , 2010, Trends in Endocrinology & Metabolism.

[22]  M. Cascio,et al.  Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. , 2010, Carcinogenesis.

[23]  B. He,et al.  The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages[S] , 2010, Journal of Lipid Research.

[24]  E. Hermans,et al.  Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. , 2010, Biochemical pharmacology.

[25]  A. Makriyannis,et al.  Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma , 2010, Journal of Lipid Research.

[26]  S. Oliet,et al.  Alterations in the Hippocampal Endocannabinoid System in Diet-Induced Obese Mice , 2010, The Journal of Neuroscience.

[27]  B. Watkins,et al.  Bone mineral content is positively correlated to n-3 fatty acids in the femur of growing rats , 2010, British Journal of Nutrition.

[28]  E. Tibiriçá The multiple functions of the endocannabinoid system: a focus on the regulation of food intake , 2010, Diabetology & metabolic syndrome.

[29]  G. Wenk,et al.  Cannabinoid agonist WIN-55,212-2 partially restores neurogenesis in the aged rat brain , 2009, Molecular Psychiatry.

[30]  J. Després,et al.  CB1 antagonists for obesity—what lessons have we learned from rimonabant? , 2009, Nature Reviews Endocrinology.

[31]  M. Collu,et al.  Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. , 2009, The Journal of nutrition.

[32]  Cheol-Whan Lee,et al.  CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. , 2009, Cardiovascular research.

[33]  E. Timofeeva,et al.  The brain endocannabinoid system in the regulation of energy balance. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[34]  V. Di Marzo,et al.  An introduction to the endocannabinoid system: from the early to the latest concepts. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[35]  A. Zimmer,et al.  Cannabinoids and the skeleton: From marijuana to reversal of bone loss , 2009, Annals of medicine.

[36]  F. Bermúdez-Silva,et al.  Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. , 2008, Endocrine, metabolic & immune disorders drug targets.

[37]  Rafael J. Yáñez-Muñoz,et al.  A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner , 2008, Molecular and Cellular Neuroscience.

[38]  U. Pagotto,et al.  Here, There and Everywhere: the Endocannabinoid System , 2008, Journal of neuroendocrinology.

[39]  K. Mackie,et al.  Cannabinoid Receptors: Where They are and What They do , 2008, Journal of neuroendocrinology.

[40]  R. Capasso,et al.  Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets , 2008, Molecular and Cellular Endocrinology.

[41]  G. Wenk,et al.  Inflammation and aging: can endocannabinoids help? , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[42]  Christian Skonberg,et al.  Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. , 2008, Biochimica et biophysica acta.

[43]  M. Elphick,et al.  Localization of N‐acyl phosphatidylethanolamine phospholipase D (NAPE‐PLD) expression in mouse brain: A new perspective on N‐acylethanolamines as neural signaling molecules , 2008, The Journal of comparative neurology.

[44]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[45]  Robin M. Murray,et al.  Cannabis, the mind and society: the hash realities , 2007, Nature Reviews Neuroscience.

[46]  J. Rodgers,et al.  Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation , 2007, Behavioural pharmacology.

[47]  D. Cota CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health , 2007, Diabetes/metabolism research and reviews.

[48]  M. Haney,et al.  Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates , 2007, Pharmacology Biochemistry and Behavior.

[49]  P. V. Piazza,et al.  Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. , 2007, Diabetes & Metabolism.

[50]  V. Marzo,et al.  Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men , 2007, International Journal of Obesity.

[51]  S. T. Boyd The Endocannabinoid System , 2006, Pharmacotherapy.

[52]  M. Fasshauer,et al.  Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.

[53]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[54]  G. Parker,et al.  Omega-3 fatty acids and mood disorders. , 2006, The American journal of psychiatry.

[55]  G. Kennett,et al.  The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake , 2006, Pharmacology Biochemistry and Behavior.

[56]  B. Watkins,et al.  Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: actions on bone mineral and serum biomarkers in ovariectomized rats. , 2006, The Journal of nutritional biochemistry.

[57]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[58]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[59]  B. Lutz,et al.  The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract , 2005, Journal of Molecular Medicine.

[60]  T. Bisogno,et al.  The endocannabinoid signalling system: Biochemical aspects , 2005, Pharmacology Biochemistry and Behavior.

[61]  M. Maj,et al.  Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa , 2005, Neuropsychopharmacology.

[62]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[63]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[64]  Z. Thornton-Jones,et al.  The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food , 2005, Psychopharmacology.

[65]  M. Korbonits,et al.  The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin , 2004, British journal of pharmacology.

[66]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[67]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[68]  R. Ross Anandamide and vanilloid TRPV1 receptors , 2003, British journal of pharmacology.

[69]  T. Horvath Endocannabinoids and the regulation of body fat: the smoke is clearing. , 2003, The Journal of clinical investigation.

[70]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[71]  T. Hamazaki,et al.  n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[72]  S. Di,et al.  Nongenomic Glucocorticoid Inhibition via Endocannabinoid Release in the Hypothalamus: A Fast Feedback Mechanism , 2003, The Journal of Neuroscience.

[73]  B. Alger Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids , 2002, Progress in Neurobiology.

[74]  D. Piomelli,et al.  A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.

[75]  G. Slama,et al.  Dietary (n-3) polyunsaturated fatty acids up-regulate plasma leptin in insulin-resistant rats. , 2002, The Journal of nutrition.

[76]  V. Marzo,et al.  Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerol , 2002, British journal of pharmacology.

[77]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[78]  K. Waku,et al.  Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[79]  N. Jamshidi,et al.  Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats , 2001, British journal of pharmacology.

[80]  T. Bisogno,et al.  Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[81]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[82]  Heping Cheng,et al.  Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses , 2001, Nature.

[83]  H. Schmid Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? , 2000, Chemistry and physics of lipids.

[84]  B. Watkins,et al.  Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. , 2000, The Journal of nutrition.

[85]  V. Di Marzo,et al.  Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period , 1999, Synapse.

[86]  T. Kirkham,et al.  Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors , 1999, Psychopharmacology.

[87]  T. Bisogno,et al.  Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. , 1999, Biochemical and biophysical research communications.

[88]  A. Inui Feeding and body-weight regulation by hypothalamic neuropeptides—mediation of the actions of leptin , 1999, Trends in Neurosciences.

[89]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[90]  M. Wartmann,et al.  The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide , 1995, FEBS letters.

[91]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[92]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[93]  M. A. Aliapoulios,et al.  Gynecomastia in marihuana users. , 1972, The New England journal of medicine.

[94]  J Mayer,et al.  Regulation of Food Intake and Obesity , 1967, Science.

[95]  D. McConnell Bone Mineral. , 1964, Science.

[96]  A. Howlett Cannabinoid receptor signaling. , 2005, Handbook of experimental pharmacology.

[97]  T. Sugiura,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.